Genmab A/S announced that it will present 14 abstracts evaluating epcoritamab at the 30th European Hematology Association (EHA) Congress, held from June 12-15, 2025. These presentations will cover epcoritamab as a monotherapy and in combination across various disease settings for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Two oral presentations will feature data from the Phase 1/2 EPCORE NHL-2 trial, evaluating epcoritamab plus R-ICE in patients with relapsed/refractory (R/R) DLBCL eligible for autologous stem cell transplantation. Another oral presentation will highlight data from the Phase 1/2 EPCORE NHL-5 trial, assessing epcoritamab plus pola-R-CHP in previously-untreated DLBCL patients.
Additionally, results from the Phase 1/2 EPCORE NHL-1 and NHL-3 trials, including three years of follow-up in patients with R/R DLBCL and FL treated with epcoritamab monotherapy, will be presented as a poster. These presentations reinforce Genmab's commitment to advancing epcoritamab as a core therapy for B-cell malignancies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.